Skip to main content
Clinical Trials/IRCT20190714044199N1
IRCT20190714044199N1
Recruiting
Phase 3

Evaluating the efficacy of adding N-Acetyl cysteine to risperidone treatment regimen in patients with autism spectrum disorder

Medical Science University of Mashhad0 sites66 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Autism spectrum disorder.
Sponsor
Medical Science University of Mashhad
Enrollment
66
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Medical Science University of Mashhad

Eligibility Criteria

Inclusion Criteria

  • Autism spectrum disorder (ASD) patients aging between 3 to 12
  • Having parental informed consent
  • IQ score greater than 50 based on Wildland Test
  • Receiving risperidone therapy for at least one month
  • Lack of clear organic disease (based on family history and medical records) Clear organic causes include visual and hearing impairment, seizures, trauma cycles, chronic or acute medical disorder, and brain dysfunction.
  • Psychiatric disorders including Toure's syndrome, Fragile X syndrome, schizophrenia, Attension deficit hyperactivity disorder (ADHD) based on structured psychiatric interview conducted by pediatric psychiatrist

Exclusion Criteria

  • If the parents do not cooperate for any reason after entering the study 2\- 3\-
  • Use of any psychotropic drugs other than risperidone
  • Any unbearable or life\-threatening drug side effect or any other illness that requires medication which may interfere with results of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials